Category Archives: Patently BIOtech

Here are the Facts about the IPR Kill Rate

US_Patent_And_Trademark_Office

FiercePhrma recently ran an article repeating a dubious analysis of the crisis caused by the rapidly increasing number of biopharma related inter partes reviews (IPR) currently within the United States Patent and Trademark Office (PTO). It is troubling that in a single breath Ronny Gal both dismissed the biopharmaceutical industry’s concerns with the PTO’s IPR process and acknowledged that limited data prevents any firm conclusions about the potential impact of IPR on biotech innovation. If Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

102 Organizations Urge Congress to Maintain a Strong Patent System and Protect Innovation

US Capitol Building

A diverse group of more than 100 national and state-based advocacy organizations have united to urge Congress to preserve important patent protections that incentivize biopharmaceutical research necessary to innovate and develop new cures and treatments for serious diseases. In a letter sent to the Hill this week, these patient advocates asked Congress to amend the Innovation Act (H.R. 9) to preserve the highly-detailed and sophisticated systems designed by Hatch-Waxman and BPCIA and avoid weakening the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Register for the 2015 BIO IP & Diagnostics Symposium!

Biotechnology Industry Organization (BIO)

The Third Annual BIO IP & Diagnostics Symposium takes place on September 18, 2015 in Alexandria, Virginia! Have you reserved your seat at the Symposium yet? Space is limited. Register today. The symposium will bring together representatives of academia, government and industry to review the current patent law landscape and evaluate the impact on both the genetic diagnostics and biopharmaceutical sectors. The program will review IP issues for both diagnostics generally and companion diagnostics. It will Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , , ,

New Report Suggests RDP Does Not Increase Healthcare Expenditures

health care, medicine

A new paper by the Geneva Network suggests that increasing the period of regulatory data protection (RDP) for biologic medicines would not increase expenditures for medicines. As countries navigate the final negotiations in the Trans-Pacific Partnership, the U.S. and Japan have advocated for increased regulatory data protection for biologic medicines by other TPP countries. In the U.S. biologics enjoy 12 years of data exclusivity; the only TPP countries, aside from the U.S, offering more than Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,

225th Anniversary of First U.S. Patent

admin-ajax

225 years ago last Friday the first U.S. patent was issued to Samuel Hopkins for an improved process for creating potash, America’s first industrial chemical compound. America’s Founding Fathers recognized Intellectual property as a fundamental right, so much so they enshrined it into our Constitution. The systems for issuing patents have changed over the years, but Congress retains the authority to regulate and change matters of patent law. Unfortunately, not all changes to patent law Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,